FDA asks Pfizer, Moderna to test their vaccines in more children to help rule out safety issues

The changes to ongoing trials run by Moderna and Pfizer and its German partner BioNTech could delay the availability of the vaccine to children between the ages of 5 and 11 beyond the hoped-for timeline of early fall, although it is unclear by how much.

View original article
Contributor: Laurie McGinley